

## **Comparative analysis of three point-of-care lateral flow immunoassays for detection of anti-SARS-CoV-2 antibodies in COVID-19 confirmed healthcare workers**

Danielle Dias Conte<sup>1</sup>, Joseane Mayara Almeida Carvalho<sup>1</sup>, Luciano Kleber de Souza Luna\*<sup>1</sup>,  
Klinger Soares Faíco-Filho<sup>1</sup>, Ana Helena Perosa<sup>2</sup>, Nancy Bellei<sup>1</sup>.

<sup>1</sup>Department of Medicine, Discipline of infectious diseases, Universidade Federal de São Paulo

<sup>2</sup>Universidade Federal de São Paulo, Hospital São Paulo

\*Corresponding author: Luciano Kleber de Souza Luna

Universidade Federal de São Paulo, Laboratório de Virologia Clínica. Rua Pedro de Toledo, 781 -  
Vila Clementino. 04039-032, São Paulo, SP, Brazil. Phone: + 55 11 5576-4848, branch 2222. E-  
mail: [lksluna@gmail.com](mailto:lksluna@gmail.com)

Danielle Dias Conte  
ORCID: 0000-0002-4351-0831

Joseane Mayara Almeida Carvalho  
ORCID: 0000-0003-1186-8895

Luciano Kleber de Souza Luna  
ORCID: 0000-0002-3552-5507

Klinger Soares Faíco-Filho  
ORCID: 0000-0003-2071-0061

Nancy Cristina Junqueira Bellei  
ORCID: 0000-0001-6080-5693

## **Abstract**

Since the Coronavirus Disease 2019 (COVID-19) pandemic, Brazil has the third-highest number of confirmed cases and the second-highest number of recovered patients. SARS-CoV-2 detection by real-time RT-PCR is the gold standard in certified infrastructured laboratories. However, for large-scale testing, diagnostics should be fast, cost-effective, widely available, and deployed for the community, such as serological tests based on lateral flow immunoassay (LFIA) for IgM/IgG detection. We evaluated three different commercial point-of-care (POC) LFIAs for anti-SARS-CoV-2 IgM and IgG detection in capillary whole blood of 100 healthcare workers (HCW) previously tested by RT-PCR: 1) COVID-19 IgG/IgM BIO (Bioclin, Brazil), 2) Diagnostic kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Livzon, China); and 3) SARS-CoV-2 Antibody Test (Wondfo, China). A total of 84 positives and 16 negatives HCW were tested. The data was also analyzed by the number of days post symptoms (DPS) in three groups: <30 (n=26), 30-59 (n=42), and >59 (n=16). Overall detection was 85.71%, 47.62%, and 44.05% for Bioclin, Livzon, and Wondfo, respectively, with a specificity of 100%, and 98.75% for Livzon on storage serum samples. Bioclin was more sensitive ( $p<0.01$ ), regardless of the DPS. Thus, the Bioclin can be used as a POC test to monitor SARS-CoV-2 seroconversion in HCW.

**Keywords:** SARS-CoV-2, COVID-19, point-of-care, lateral flow immunoassay, healthcare workers.

## 1. Introduction

After almost seven months since the Coronavirus Disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Brazil reached, until late November 2020, the third place in the number of confirmed cases, accounting for more than 6,1 million cases and 170 thousand deaths. However, is the second country with the highest number of recovered patients ( more than 5,5 million) [1].

The molecular detection of SARS-CoV-2 by real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) is the gold standard test but requires a certified laboratory infrastructure with high-cost equipment and trained personnel. This structure is suitable, and of paramount importance, for the diagnostic of hospitalized patients, as well as healthcare workers (HCW). However, for large-scale testing, RT-PCR is not the best option. Therefore, COVID-19 diagnostic tests should be fast, cost-effective, widely available, and deployed for the community. In general, those requisites are achieved by serological tests based on lateral flow immunoassay (LFIA). Many LFIAs have been described for the detection of IgM and IgG immunoglobulins against SARS-CoV-2 [2].

Immunoglobulin response against viral infection begins with an early and transient IgM production, followed by a longer and lasting IgG response. In patients with COVID-19, the production of IgM and IgG could be simultaneous and detected after two days of symptoms onset, and could reach in some patients a plateau level after six days [3, 4]. Moreover, the immunoglobulin levels are correlated positively with the severity of COVID-19 although the antibody response could be delayed in critical patients compared to non-critical cases [5].

In the present study, we evaluated the sensitivity of three different commercial point-of-care (POC) LFIAs for anti-SARS-CoV-2 antibody detection, in HCW with confirmed tests (positive or negative) for COVID-19 by real-time RT-PCR assay.

## 2. Material and methods

Three commercial POC LFIAs for detection of anti-SARS-CoV-2 IgG and IgM were tested: 1) COVID-19 IgG/IgM BIO (Bioclin, Brazil), 2) Diagnostic kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Livzon, China); and 3) SARS-CoV-2 Antibody Test (Wondfo, China). Bioclin and Livzon LFIAs independently detect IgG and IgM, whereas Wondfo detects IgG and IgM combined. In brief, these tests detect IgG and IgM immunoglobulins anti-SARS-CoV-2, in a lateral flow assay, that react with colloidal gold particles conjugated with SARS-CoV-2 antibodies, which in turn are captured by antibodies against human IgM and IgG present in the Test Region (T), resulting in a dark-colored test band (positive result). A second Control Region (C) is present indicating a valid test when a dark-colored band is also generated, or invalid otherwise.

A total of 100 HCW from the university Hospital São Paulo, previously tested for SARS-CoV-2 infection by real-time RT-PCR, were enrolled in the study. From them, 84 were confirmed positive, and 16, negative.

The indicated volume of finger-prick capillary whole blood for each test, collected preferably from the skin of annular fingertip with a lancing device, was added immediately into the cassette sample wells, following the addition of sample diluent according to the manufacturer instructions. All LFIAs were tested simultaneously in the moment of blood draw of each investigated HCW. Results were read within 1-15 minutes.

The sensitivity was calculated as the proportion of positive results of LFIAs in relation to the positive RT-PCR confirmed cases, and specificity was calculated as the proportion of LFIAs negative results in relation to the negative RT-PCRs. The 95% confidence intervals (CI) of sensitivity and specificity proportions were calculated by the modified Wald method. The results were also analyzed according to the number of days post symptoms (DPS), distributed in three distinct groups: <30 (n=26), 30-59 (n=42), and >59 (n=16). The proportion of results accounted for IgM and IgG, alone or combined, regarding DPS, and the pairwise comparison within LFIAs was

analyzed by Cochran's Q and McNemar tests, for a  $p$ -value  $<0.05$ . The analysis was made using software R version 4.0.2 [6].

The study was approved by the São Paulo hospital Research Ethics Committee (CEP n. 34371020.5.0000.5505).

### 3. Results

The age of investigated HCWs varied from 20 to 67 years (mean = 37.45, median = 36). Overall detection of IgM and IgG, individually or combined, are described in table 1.

**Table 1:** Comparison of LFIA results with 84 positive RT-PCR for SARS-CoV-2.

LFIA	number / Sensitivity in % (95% CI)		
	IgG/IgM	IgM	IgG
Bioclin	72 / 85.71 (76.52-91.79)	46 / 54.76 (44.14-64.97)	72 / 85.71 (76.52-91.79)
Livzon	40 / 47.62 (37.28-58.17)	25 / 29.76 (21.01-40.29)	54 / 35.71 (26.28-46.40)
Wondfo	37 / 44.05 (33.92-54.70)	N.A.	N.A.

N.A., not available.

In general, Bioclin LFIA showed the highest sensitivity (85.71%), followed by Livzon (47.62%) and Wondfo (44.05%). In comparison to the 16 negative RT-PCR individuals, the sensitivity of all LFIA was 100% (77.31% to 100%, 95% CI).

The results according to the groups of DPS (<30, 30-59, and >59), are depicted in table 2.

**Table 2:** Comparison of LFIA results in time groups according to the days post symptoms (DPS).

Antibody	DPS	HCW	number (%)			<i>p-value</i>
			Bioclin	Wondfo	Livzon	
IgM/IgG <sup>1</sup>	<30	26	22 (84.62)	14 (53.85)	13 (50.00)	0.0022*
	30-59	42	38 (90.48)	21 (50.00)	17 (40.48)	<0.001*
	>59	16	12 (75.00)	5 (31.25)	7 (43.75)	0.0131*
IgM <sup>2</sup>	<30	26	19 (73.08)	NA	11 (42.31)	0.0047*
	30-59	42	21 (50.00)	NA	11 (26.19)	0.03892*
	>59	16	6 (37.50)	NA	3 (18.75)	0.0833
IgG <sup>2</sup>	<30	26	22 (84.62)	NA	10 (38.46)	0.0005*
	30-59	42	38 (90.48)	NA	15 (35.71)	<0.001*
	>59	16	12 (75.00)	NA	5 (31.25)	0.0081

DPS, days post symptoms. HCW, healthcare workers.

\*significant for  $p < 0.05$

<sup>1</sup>Cochran's Q test,  $p < 0.05$

<sup>2</sup>McNemar test,  $p < 0.05$

The Bioclin LFIA was significantly more sensitive, in comparison to Livzon and Wondfo, regardless of the DPS or detection of IgM and IgG combined (Cochran's Q test,  $p < 0.05$ ). The posthoc analysis of pairwise comparisons with McNemar tests also have shown that Bioclin was more sensitive than Livzon for IgM and IgG individually, and no differences were observed between Livzon and Wondfo regardless of the DPS and immunoglobulin class (table 2).

The proportion of positives within each LFIA in relation to the DPS have shown any significant difference for overall IgM and IgG detection (Bioclin,  $p = 0.316$ ; Livzon,  $p = 0.744$ ; Wondfo,  $p = 0.33$ ), although the sensibility of Wondfo LFIA dropped to 31.25% after 60 DPS. The same was observed for IgG (Bioclin,  $p = 0.316$ ; Livzon,  $p = 0.894$ ) and IgM (Bioclin,  $p = 0.054$ ; Livzon,  $p = 0.208$ ) alone, although Bioclin is likely to be more sensitive for IgM in the group of  $< 30$  ( $p = 0.054$ ).

We also observed in the Wondfo LFIA test a trace of red blood cells in all lateral flow test cassettes which made reading difficult in some cases of weak positives.

#### 4. Discussion

In the present study, we analyzed three different commercial LFIAs for the detection of anti-SARS-CoV-2 IgG and IgM in HCW. For the POC test format, capillary whole blood is more suitable than serum or plasma and does not require a laboratory infrastructure for venous blood draw.

The use of POC based tests for rapid antibody detection can be helpful in identifying patients at different stages of infection, due to the early production of IgM followed by IgG response, although, in patients with COVID-19, the response of IgM and IgG could be simultaneous. Our results demonstrated that overall sensitivity achieved by Bioclin LFIA (85.71%) with whole blood samples is compared to those obtained with serum or plasma, in contrast to Livzon and Wondfo LFIAs which showed sensitivities below 50% [7-10].

Similar to the results here described, Santos et al. [8] have shown, for capillary whole blood, a sensitivity of 55% for the Wondfo LFIA test in HCWs, while the sensitivity in serum samples was much higher (96%). A better sensitivity for capillary whole blood with Wondfo LFIA test was reported by Silveira et al. [9] at 77.1% in 83 volunteers with positive RT-PCR results at least 10 days before the LFIA test. In a larger study with hospitalized patients, Costa et al. [7] evaluated the Wondfo LFIA, in serum samples or plasma, and obtained a sensitivity of 85.8%. In another evaluation of the Wondfo LFIA, Wu et al. [11] have shown a sensibility of 75.8% in serum samples. In the same manner, the Livzon LFIA, when tested in serum samples of hospitalized patients, presented a sensibility of 80% for IgM and 86.7 for IgG, with a specificity of 95% and 100% respectively.

In summary, for LFIA, antibody detection is more effective in plasma or serum samples than in whole blood, although, for POC format and large-scale testing, finger-prick capillary whole blood is more appropriate, and therefore, choosing a more sensitive test for this type of sample is of paramount importance. In this regard, Hallal et al. [12] extrapolated the sensitivity of Wondfo LFIA at 84.8%, based on pooled results of three validation studies using plasma or serum, with sensitivities varying from 81.5% to 100%, and one using whole blood (77.1%), in two nationwide

surveys on the SARS-CoV-2 antibody prevalence in Brazil but using finger-prick whole blood. On that account, antibody prevalence could have been considerably underestimated.

An advantage of the present study is due to the fact that all LFIAs were carried out simultaneously at the time of blood draw of each HCW. On the other hand, a limitation of the study was the impossibility of follow up on each HCW to observe possible variations in the detection of IgM and IgG over time, or to expand the study to include hospitalized patients or low-income individuals from the general community.

## **5. Conclusion**

Bioclin LFIA demonstrated high sensitivity and specificity for IgG detection (85.71%), and a reasonable detection of IgM (54.76%), with the use of capillary whole blood in HCW. On the other hand, Livzon and Wondfo LFIAs presented overall sensitivity below 50%. Thus, the Bioclin LFIA is a suitable POC test to monitor SARS-CoV-2 seroconversion in HCW.

## **Acknowledgments**

J.M.A.C. and L.K.S.L. are fellows of the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil. D.D.C. is a fellow of the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil. We are grateful to Anderson Scorsato for the statistical support.

**Declarations of interest:** none

## **CRedit authorship contribution statement**

**Danielle D. Conte:** Validation, Investigation, Data Curation, Writing - Original Draft. **Joseane M. A. Carvalho:** Investigation, Data Curation. **Luciano K. de Souza Luna:** Validation, Investigation, Formal analysis, Writing - Review & Editing, Visualization. **Klinger S. Faíco-Filho:** Investigation.



**Ana H. S. Perosa:** Investigation. **Nancy Bellei:** Conceptualization, Methodology, Resources, Supervision, Writing - Review & Editing, Project administration, Funding acquisition.

## References

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis.* 2020 May;20(5):533-4. doi:10.1016/S1473-3099(20)30120-1.
2. Vashist SK. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. *Diagnostics (Basel).* 2020 Apr 5;10(4). doi:10.3390/diagnostics10040202.
3. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med.* 2020 Jun;26(6):845-8. doi:10.1038/s41591-020-0897-1.
4. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis.* 2020 Mar 28. doi:10.1093/cid/ciaa344.
5. Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis.* 2020 Apr 27. doi:10.1093/cid/ciaa489.
6. Team RC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.
7. Costa SF, Buss L, Espinoza EPS, Vieira JM, Jr., de Oliveira da Silva LC, de Souza RM, et al. Performance of a qualitative rapid chromatographic immunoassay to diagnose COVID-19 in patients in a middle-income country. *J Clin Virol.* 2020 Aug 14;131:104592. doi:10.1016/j.jcv.2020.104592.
8. Santos VAD, Rafael MM, Sabino EC, Duarte A. Sensitivity of the Wondfo One Step COVID-19 test using serum samples. *Clinics (Sao Paulo).* 2020 Jun 3;75:e2013. doi:10.6061/clinics/2020/e2013.
9. Silveira MF, Barros AJD, Horta BL, Pellanda LC, Victora GD, Dellagostin OA, et al. Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil. *Nat Med.* 2020 Aug;26(8):1196-9. doi:10.1038/s41591-020-0992-3.
10. Tuaille E, Bollore K, Pisoni A, Debieesse S, Renault C, Marie S, et al. Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients. *J Infect.* 2020 Aug;81(2):e39-e45. doi:10.1016/j.jinf.2020.05.077.
11. Wu JL, Tseng WP, Lin CH, Lee TF, Chung MY, Huang CH, et al. Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2. *J Infect.* 2020 Jun 15. doi:10.1016/j.jinf.2020.06.023.
12. Hallal PC, Hartwig FP, Horta BL, Silveira MF, Struchiner CJ, Vidaletti LP, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. *Lancet Glob Health.* 2020 Nov;8(11):e1390-e8. doi:10.1016/S2214-109X(20)30387-9.